With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management ...
JD Supra13h
GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from its Drug Shortage List
On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
News Medical on MSN1d
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...
FiercePharma1d
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Glamour on MSN4d
Do GLP-1 Supplements Work? Doctors Set the Record Straight on ‘Nature’s Ozempic’
Brands like Kourtney Kardashian’s Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...
Psychology Today7d
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...
MedPage Today7d
Food Retention Risk Low for GLP-1 Users When Endoscopy Is Combined With Colonoscopy
"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...
Business Wire5d
Digbi Health to Present Groundbreaking Study on Gut Microbiome's Role in Enhancing Endogenous GLP-1 Production at 2024 Obesity Society Conference
Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the ...
GLP-1 drug demand rising, but not all packaged foods companies in the crosshairs
As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than ...